Selecta Biosciences, Inc.
NASDAQ: SELB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Carsten Brunn
- Employees
- 64
- Headquarters
- Watertown, United States
- IPO year
- 2016
- Market cap
- $135.2M
- Website
- https://selectabio.com
Loading SELB…
Loading profile data…Frequently asked questions about SELB
What does Selecta Biosciences, Inc. (SELB) do?
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to the research and development of innovative nanoparticle immunomodulatory medications aimed at treating and preventing various human ailments. The company's most advanced gene therapy initiative is SEL-302, currently in preclinical development to enhance therapeutic...
Where does SELB trade?
Selecta Biosciences, Inc. (SELB) trades on the NASDAQ Global Market.
What sector is SELB in?
Selecta Biosciences, Inc. (SELB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Selecta Biosciences, Inc.?
Carsten Brunn is the chief executive officer of Selecta Biosciences, Inc. (SELB).
Where is Selecta Biosciences, Inc. headquartered?
Selecta Biosciences, Inc. is headquartered in United States.
Does SELB pay a dividend?
Selecta Biosciences, Inc. (SELB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SELB go public?
Selecta Biosciences, Inc. (SELB) completed its initial public offering in 2016.